Copyright Reports & Markets. All rights reserved.

COVID-19 Impact on Global CNS Specific Antisense Oligonucleotides Market Report, History and Forecast 2015-2026, Breakdown Data by Companies, Key Regions, Types and Application

Request for Sample of this report
Buy now

1 Market Overview of CNS Specific Antisense Oligonucleotides

  • 1.1 CNS Specific Antisense Oligonucleotides Market Overview
    • 1.1.1 CNS Specific Antisense Oligonucleotides Product Scope
    • 1.1.2 Market Status and Outlook
  • 1.2 Global CNS Specific Antisense Oligonucleotides Market Size Overview by Region 2015 VS 2020 VS 2026
  • 1.3 Global CNS Specific Antisense Oligonucleotides Market Size by Region (2015-2026)
  • 1.4 Global CNS Specific Antisense Oligonucleotides Historic Market Size by Region (2015-2020)
  • 1.5 Global CNS Specific Antisense Oligonucleotides Market Size Forecast by Region (2021-2026)
  • 1.6 Key Regions, CNS Specific Antisense Oligonucleotides Market Size YoY Growth (2015-2026)
    • 1.6.1 North America CNS Specific Antisense Oligonucleotides Market Size YoY Growth (2015-2026)
    • 1.6.2 Europe CNS Specific Antisense Oligonucleotides Market Size YoY Growth (2015-2026)
    • 1.6.3 Asia-Pacific CNS Specific Antisense Oligonucleotides Market Size YoY Growth (2015-2026)
    • 1.6.4 Latin America CNS Specific Antisense Oligonucleotides Market Size YoY Growth (2015-2026)
    • 1.6.5 Middle East & Africa CNS Specific Antisense Oligonucleotides Market Size YoY Growth (2015-2026)

2 CNS Specific Antisense Oligonucleotides Market Overview by Type

  • 2.1 Global CNS Specific Antisense Oligonucleotides Market Size by Type: 2015 VS 2020 VS 2026
  • 2.2 Global CNS Specific Antisense Oligonucleotides Historic Market Size by Type (2015-2020)
  • 2.3 Global CNS Specific Antisense Oligonucleotides Forecasted Market Size by Type (2021-2026)
  • 2.4 Polyneuropathy Treatment
  • 2.5 Spinal Muscular Atrophy (SMA) Treatment
  • 2.6 Huntington’s Disease Treatment

3 CNS Specific Antisense Oligonucleotides Market Overview by Application

  • 3.1 Global CNS Specific Antisense Oligonucleotides Market Size by Application: 2015 VS 2020 VS 2026
  • 3.2 Global CNS Specific Antisense Oligonucleotides Historic Market Size by Application (2015-2020)
  • 3.3 Global CNS Specific Antisense Oligonucleotides Forecasted Market Size by Application (2021-2026)
  • 3.4 Hospital Pharmacies
  • 3.5 Retail Pharmacies
  • 3.6 Online Pharmacies

4 Global CNS Specific Antisense Oligonucleotides Competition Analysis by Players

  • 4.1 Global CNS Specific Antisense Oligonucleotides Market Size by Players (2015-2020)
  • 4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in CNS Specific Antisense Oligonucleotides as of 2019)
  • 4.3 Date of Key Manufacturers Enter into CNS Specific Antisense Oligonucleotides Market
  • 4.4 Global Top Players CNS Specific Antisense Oligonucleotides Headquarters and Area Served
  • 4.5 Key Players CNS Specific Antisense Oligonucleotides Product Solution and Service
  • 4.6 Competitive Status
    • 4.6.1 CNS Specific Antisense Oligonucleotides Market Concentration Rate
    • 4.6.2 Mergers & Acquisitions, Expansion Plans

5 Company (Top Players) Profiles and Key Data

  • 5.1 Akcea Therapeutics, Inc.
    • 5.1.1 Akcea Therapeutics, Inc. Profile
    • 5.1.2 Akcea Therapeutics, Inc. Main Business
    • 5.1.3 Akcea Therapeutics, Inc. CNS Specific Antisense Oligonucleotides Products, Services and Solutions
    • 5.1.4 Akcea Therapeutics, Inc. CNS Specific Antisense Oligonucleotides Revenue (US$ Million) & (2015-2020)
    • 5.1.5 Akcea Therapeutics, Inc. Recent Developments
  • 5.2 Ionis Pharmaceuticals Inc.
    • 5.2.1 Ionis Pharmaceuticals Inc. Profile
    • 5.2.2 Ionis Pharmaceuticals Inc. Main Business
    • 5.2.3 Ionis Pharmaceuticals Inc. CNS Specific Antisense Oligonucleotides Products, Services and Solutions
    • 5.2.4 Ionis Pharmaceuticals Inc. CNS Specific Antisense Oligonucleotides Revenue (US$ Million) & (2015-2020)
    • 5.2.5 Ionis Pharmaceuticals Inc. Recent Developments
  • 5.3 Biogen Inc.
    • 5.5.1 Biogen Inc. Profile
    • 5.3.2 Biogen Inc. Main Business
    • 5.3.3 Biogen Inc. CNS Specific Antisense Oligonucleotides Products, Services and Solutions
    • 5.3.4 Biogen Inc. CNS Specific Antisense Oligonucleotides Revenue (US$ Million) & (2015-2020)
    • 5.3.5 Sarepta Therapeutics Recent Developments
  • 5.4 Sarepta Therapeutics
    • 5.4.1 Sarepta Therapeutics Profile
    • 5.4.2 Sarepta Therapeutics Main Business
    • 5.4.3 Sarepta Therapeutics CNS Specific Antisense Oligonucleotides Products, Services and Solutions
    • 5.4.4 Sarepta Therapeutics CNS Specific Antisense Oligonucleotides Revenue (US$ Million) & (2015-2020)
    • 5.4.5 Sarepta Therapeutics Recent Developments
  • 5.5 Wave Life Sciences Ltd.
    • 5.5.1 Wave Life Sciences Ltd. Profile
    • 5.5.2 Wave Life Sciences Ltd. Main Business
    • 5.5.3 Wave Life Sciences Ltd. CNS Specific Antisense Oligonucleotides Products, Services and Solutions
    • 5.5.4 Wave Life Sciences Ltd. CNS Specific Antisense Oligonucleotides Revenue (US$ Million) & (2015-2020)
    • 5.5.5 Wave Life Sciences Ltd. Recent Developments
  • 5.6 Dynacure
    • 5.6.1 Dynacure Profile
    • 5.6.2 Dynacure Main Business
    • 5.6.3 Dynacure CNS Specific Antisense Oligonucleotides Products, Services and Solutions
    • 5.6.4 Dynacure CNS Specific Antisense Oligonucleotides Revenue (US$ Million) & (2015-2020)
    • 5.6.5 Dynacure Recent Developments
  • 5.7 ProQR Therapeutics N.V.
    • 5.7.1 ProQR Therapeutics N.V. Profile
    • 5.7.2 ProQR Therapeutics N.V. Main Business
    • 5.7.3 ProQR Therapeutics N.V. CNS Specific Antisense Oligonucleotides Products, Services and Solutions
    • 5.7.4 ProQR Therapeutics N.V. CNS Specific Antisense Oligonucleotides Revenue (US$ Million) & (2015-2020)
    • 5.7.5 ProQR Therapeutics N.V. Recent Developments
  • 5.8 Stroke Therapeutic Inc.
    • 5.8.1 Stroke Therapeutic Inc. Profile
    • 5.8.2 Stroke Therapeutic Inc. Main Business
    • 5.8.3 Stroke Therapeutic Inc. CNS Specific Antisense Oligonucleotides Products, Services and Solutions
    • 5.8.4 Stroke Therapeutic Inc. CNS Specific Antisense Oligonucleotides Revenue (US$ Million) & (2015-2020)
    • 5.8.5 Stroke Therapeutic Inc. Recent Developments

6 North America

  • 6.1 North America CNS Specific Antisense Oligonucleotides Market Size by Country
  • 6.2 United States
  • 6.3 Canada

7 Europe

  • 7.1 Europe CNS Specific Antisense Oligonucleotides Market Size by Country
  • 7.2 Germany
  • 7.3 France
  • 7.4 U.K.
  • 7.5 Italy
  • 7.6 Russia
  • 7.7 Nordic
  • 7.8 Rest of Europe

8 Asia-Pacific

  • 8.1 Asia-Pacific CNS Specific Antisense Oligonucleotides Market Size by Region
  • 8.2 China
  • 8.3 Japan
  • 8.4 South Korea
  • 8.5 Southeast Asia
  • 8.6 India
  • 8.7 Australia
  • 8.8 Rest of Asia-Pacific

9 Latin America

  • 9.1 Latin America CNS Specific Antisense Oligonucleotides Market Size by Country
  • 9.2 Mexico
  • 9.3 Brazil
  • 9.4 Rest of Latin America

10 Middle East & Africa

  • 10.1 Middle East & Africa CNS Specific Antisense Oligonucleotides Market Size by Country
  • 10.2 Turkey
  • 10.3 Saudi Arabia
  • 10.4 UAE
  • 10.5 Rest of Middle East & Africa

11 CNS Specific Antisense Oligonucleotides Market Dynamics

  • 11.1 Industry Trends
  • 11.2 Market Drivers
  • 11.3 Market Challenges
  • 11.4 Market Restraints

12 Research Finding /Conclusion

    13 Methodology and Data Source

    • 13.1 Methodology/Research Approach
      • 13.1.1 Research Programs/Design
      • 13.1.2 Market Size Estimation
      • 13.1.3 Market Breakdown and Data Triangulation
    • 13.2 Data Source
      • 13.2.1 Secondary Sources
      • 13.2.2 Primary Sources
    • 13.3 Disclaimer

    Antisense oligonucleotides are single-stranded oligodeoxynucleotides that can alter the RNA and modify protein expression. These oligonucleotides were discovered to influence RNA processing. Subsequent chemical modifications of antisense oligonucleotides were used to address issues such as off-target toxic effects and insufficient biological activity. These modifications led to an improved mechanism of antisense oligonucleotides and clinical trial design. This paved the way toward translating their use into therapies for various genetic and neurological conditions. Antisense oligonucleotides mediated therapies target the source of pathogenesis and have higher chance of success as compared to therapies that target downstream pathways. These are drugs for the treatment of central nervous system (CNS) disorders, as they have specific molecular targeting and extended pharmacological properties.

    Market Analysis and Insights: Global CNS Specific Antisense Oligonucleotides Market
    The research report studies the CNS Specific Antisense Oligonucleotides market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
    The global CNS Specific Antisense Oligonucleotides market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
    Global CNS Specific Antisense Oligonucleotides Scope and Segment
    The global CNS Specific Antisense Oligonucleotides market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global CNS Specific Antisense Oligonucleotides market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2015-2026.
    by Type, the market is primarily split into
    Polyneuropathy Treatment
    Spinal Muscular Atrophy (SMA) Treatment
    Huntington’s Disease Treatment
    by Application, this report covers the following segments
    Hospital Pharmacies
    Retail Pharmacies
    Online Pharmacies
    Global CNS Specific Antisense Oligonucleotides market: regional analysis, the major regions covered in the report are:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa
    The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
    The CNS Specific Antisense Oligonucleotides key players in this market include:
    Akcea Therapeutics, Inc.
    Ionis Pharmaceuticals Inc.
    Biogen Inc.
    Sarepta Therapeutics
    Wave Life Sciences Ltd.
    Dynacure
    ProQR Therapeutics N.V.
    Stroke Therapeutic Inc.
    Buy now